NCT04685590进行中（未招募）2 期
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
- 试验地点
- 5
- 主要终点
- Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group
研究概览
简要总结
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
详细描述
This study is a Phase II multi-site, randomized, double-blind placebo controlled trial to determine safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages 60 years and older at study entry
- •All ethnicities
- •Diagnosis of amnestic mild cognitive impairment (aMCI) or early Alzheimer's disease (AD)
- •Elevated tau protein as determined by CSF performed during screening. Evidence of elevated tau from previously available CSF samples will also be allowed for eligibility determination.
- •FDA-approved medications for AD (e.g. donepezil, rivastigmine, galantamine) are permitted as long as the participant has been maintained on a stable dose for at least three months prior to study entry.
- •Labs: Normal blood cell counts, normal liver and renal function without clinically significant excursions as determined by coordinating center Medical Monitor. Total cholesterol <240 mg/dl, HbA1c ≤ 7%.
- •Prothrombin Time (PT)/Partial Thromboplastin Time (PTT)/International Normalized Ratio (INR) within normal limits.
- •Participants must have the ability to provide written consent or be accompanied by a Legally Authorized Representative designated to sign informed consent (if determined not to have decision capacity).
- •Participants must have a study partner who agrees to participate throughout the duration of the study. The study partner must have frequent and sufficient contact (approximately 10 hours per week) with the participant and be able to provide accurate information regarding the participant's cognitive and functional abilities.
- •Participants must have no travel plans that would interfere with scheduling visits following consent over the 12 months of study duration.
- •Must speak English fluently and have at least six years of formal education.
- •Participants must be fully vaccinated against COVID-19 with the primary vaccine series per CDC recommendations, with any dose of the vaccine received at least 30 days prior to initiation of the study drug. COVID boosters are allowed during study intervention period when scheduled at least four days before or after administration of the investigational product.
排除标准
- •Body mass index (BMI)>40 kg/m
- •Average QTcF (from 3 ECGs obtained at least one minute apart) at screening of ≥450msec in males and ≥460msec in females.
- •MRI contraindications including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker.
- •Pregnancy or possible pregnancy.
- •Any significant neurologic disease other than prodromal or early AD including Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
- •Current or history of alcohol or substance abuse or dependence within the past 2 years per Diagnostic and Statistical Manual of Mental Disorders (DSM V criteria).
- •Endorsement of current suicidality or suicidal ideation on the screening C-SSRS.
- •Uncontrolled diabetes (HbA1c > 7% or the current use of insulin or sulfonylureas).
- •Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg) based on two or more readings and as determined by the PI/study clinician.
- •eGFR < 10 ml/ min/ 1.73 m
- •Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months.
- •Chronic heart failure.
- •Presence of significant liver disease with total bilirubin >2X upper limit.
- •Inability to tolerate oral medication.
- •Participants taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus, or sirolimus).
- •Participants currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy.
- •Participants on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.) other than low dose aspirin unless able to be held for 2 days prior to LP and with the documented approval of the prescribing clinician.
- •Participants taking H2 antagonists or proton pump inhibitors who are unable or unwilling to reduce or hold therapy for at least 2 days prior to and during each of the 2-day courses of Dasatinib plus quercetin dosing. Instead, subjects may use antacids prior to and during each of the 2-day courses of Dasatinib plus quercetin dosing.
- •Concomitant use of strong CYP3A4 inhibitors.
- •Co-enrollment in another ADRD research study with a potentially disease-modifying intervention or study drug that may impact senescent cells. Participants previously enrolled in a study meeting these criteria are eligible to screen after a washout period of ≥6 months from date of last dose to date of screening.
- •Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.
- •Use of anti-amyloid therapies (e.g. aducanumab, lecanamab).
研究组 & 干预措施
Treatment
Experimental
Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
干预措施: Dasatinib + Quercetin (Drug)
Placebo
Placebo Comparator
Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
干预措施: Placebo Capsules (Other)
结局指标
主要结局
Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group
时间窗: Baseline to Week 48
Adverse Events (AEs) and SAEs will be collected at each in-person visit and at scheduled telephone visits from baseline to week 48. Incidence of SAEs between groups (treatment vs. placebo) will be reviewed by the Data Safety Monitoring Board (DSMB) for clinical significance.
次要结局
- Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood(Baseline to Week 12)
- Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood(Baseline to Week 12)
- Change in cellular senescence blood marker T cells in blood(Baseline to Week 12)
- Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score(Baseline to Week 12)
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope(Baseline to Week 48)
- Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology(Baseline to Week 48)
- Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope(Baseline to Week 48)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungAdenocarcinomaNCT02875340ValiSeek Limited8
进行中（未招募）
2 期
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesGastrointestinal Tract MalignanciesNCT05329766Arcus Biosciences, Inc.332
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
招募中
1 期
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseSickle Cell DiseaseNCT06546670Novartis Pharmaceuticals161
进行中（未招募）
1 期
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung CancerNon-small Cell Lung CancerNCT06114511Sichuan Baili Pharmaceutical Co., Ltd.78